PF 5208766
Alternative Names: WAY-178357Latest Information Update: 29 Sep 2010
At a glance
- Originator Pfizer
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 Sep 2010 Discontinued - Phase-I for Cancer in USA (unspecified route)
- 27 Jan 2010 Phase-I clinical trials in Cancer in USA (unspecified route)